SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-129308
Filing Date
2021-04-23
Accepted
2021-04-23 17:24:58
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A d126948ddefa14a.htm DEFA14A 15697
2 GRAPHIC g126948dsp002.jpg GRAPHIC 255264
3 GRAPHIC g126948page003.jpg GRAPHIC 50949
  Complete submission text file 0001193125-21-129308.txt   433241
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39112 | Film No.: 21850761
SIC: 2836 Biological Products, (No Diagnostic Substances)